Antonio Arrieta
Pediatric Infectious Diseases · Orange, CANPI 1861599748
Payments from drug & device makers
Across 585 payments — averaging $5999.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.4M
- Astellas Pharma Global Development$355K
- Merck$340K
- Melinta Therapeutics, LLC$123K
- Paratek Pharmaceuticals, Inc.$99K
- Astellas US Technologies$57K
- plus $94K from 16 others
Across 23 payments — averaging $242.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$4K
- Melinta Therapeutics, LLC$2K
What the payments were for
- Consulting fees$61,65458%
- Speaking & faculty fees$14,21013%
- Travel & lodging$28,52327%
- Food & beverage$2,1522%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $2,441,373 |
| Astellas Pharma Global Development | 36 | $354,515 |
| Merck | 171 | $339,995 |
| Melinta Therapeutics, LLC | 69 | $123,065 |
| Paratek Pharmaceuticals, Inc. | 29 | $99,319 |
| Astellas US Technologies | 179 | $57,117 |
| Hoffmann-la Roche Limited | 10 | $33,257 |
| Cumberland Pharmaceuticals, Inc. | 8 | $15,990 |
| Astellas Pharma US Inc | 16 | $13,352 |
| HRA Pharma | 1 | $7,500 |
| Regeneron | 2 | $5,750 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $5,110 |
| GSK | 5 | $4,830 |
| Shionogi Inc | 1 | $4,410 |
| F. Hoffmann-la Roche AG | 1 | $1,763 |
| Inova Diagnostics, Inc. | 2 | $1,364 |
| Gilead | 6 | $568 |
| Sanofi Pasteur Inc. | 3 | $320 |
| Cook Medical LLC | 1 | $164 |
| Mesoblast, Inc. | 1 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Abbott | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,509,842 in reported general payments places this provider in the 95th percentile of 83 pediatric infectious diseases providers in California.
See all pediatric infectious diseases providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $45,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $568 | $45,51813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 83 pediatric infectious diseases providers in California.
Other pediatric infectious diseases in Orange
- Negar AshouriOrange$44K
- Jasjit SinghOrange$1K
- Shaheen IdriesOrange$650
- Aaron ShawOrange$528
- Felice Adler-ShohetOrange$388
- Yvonne MaldonadoStanford$4.9M
- Stephen SpectorSan Diego$3.5M
- John BradleySan Diego$1.9M
- Jaime DevilleLos Angeles$1.8M
- Audra DeveikisLong Beach$901K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.